Detail akcie Viatris Rg-WI online

Business Summary: Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Viatris Inc revenues decreased 4% to $14.74B. Net loss totaled $634.2M vs. income of $54.7M. Revenues reflect Developed markets segment decrease of 3% to $8.93B, Emerging Markets segment decrease of 12% to $2.25B, JANZ segment decrease of 5% to $1.35B. Net loss reflects Developed markets segment income decrease of 6% to $3.85B, Emerging Markets segment income decrease of 14% to $934.1M.